What medications are used in the treatment of substance use disorders?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Comprehensive Medication List for Addiction Treatment

Pharmacological treatments are available for opioid, alcohol, tobacco, benzodiazepine, and cannabis use disorders, with the strongest evidence supporting medication-assisted treatment for opioid and alcohol use disorders to reduce morbidity and mortality. 1, 2

Medications by Substance Use Disorder

Opioid Use Disorder (OUD)

Three FDA-approved medications exist for OUD, all of which reduce nonmedical opioid use and risk of overdose death:

  • Buprenorphine (partial mu-opioid agonist)

    • Sublingual buprenorphine alone (Subutex)
    • Buprenorphine/naloxone combination (Suboxone) - preferred formulation due to abuse-deterrent properties 1, 3
    • Long-acting injectable formulations
    • FDA-approved for patients ≥16 years 3
    • Longer-term maintenance treatment is superior to brief tapers - associated with lower relapse rates 1, 3
  • Methadone (full mu-opioid agonist)

    • Restricted to federally regulated narcotic treatment programs
    • Cannot be prescribed from office-based practices 1
  • Naltrexone (opioid antagonist)

    • Oral formulation (Revia)
    • Extended-release injectable formulation
    • Can be prescribed from office-based practices 1, 2
    • Requires complete opioid withdrawal before initiation
    • Best for highly motivated patients 2

Alcohol Use Disorder (AUD)

Six medications are approved globally for AUD, with different mechanisms targeting consumption reduction versus abstinence maintenance: 4

For reducing alcohol consumption (first-line):

  • Nalmefene (opioid antagonist)
  • Naltrexone (oral or extended-release injectable)

For maintaining abstinence (first-line):

  • Acamprosate (modulates glutamatergic/GABAergic systems)

Second-line options:

  • Disulfiram (aldehyde dehydrogenase inhibitor - aversive therapy)
    • Best for highly motivated patients in supervised settings
  • Baclofen (GABA-B agonist)
    • Particularly useful in liver disease
  • Sodium oxybate (GHB precursor)
    • For severe AUD or protracted withdrawal syndrome

All FDA-approved AUD medications reduce alcohol use and improve HIV outcomes when combined with antiretroviral therapy 2, 4

Tobacco/Nicotine Use Disorder

Multiple FDA-approved pharmacotherapies exist for tobacco cessation, strongly recommended given excess cardiovascular mortality in people with HIV: 2

  • Nicotine replacement therapy (patches, gum, lozenges, inhalers, nasal spray)
  • Varenicline (nicotinic receptor partial agonist)
  • Bupropion (norepinephrine-dopamine reuptake inhibitor)

Cannabis Use Disorder

Emerging evidence supports:

  • Gabapentinoids - may decrease withdrawal symptoms 5
  • Cannabinoids (e.g., dronabinol, nabilone) - appear to decrease use and withdrawal symptoms 5

Stimulant Use Disorders (Cocaine, Methamphetamine)

No FDA-approved medications currently exist. 2

Evidence-based approaches include:

  • Contingency management (behavioral intervention with financial incentives) - most efficacious treatment, strongly recommended 2
  • Emerging pharmacological options under investigation:
    • Stimulant medications (may reduce cravings and increase abstinence in cocaine use disorder) 5
    • Modafinil 5
    • Topiramate
    • Mirtazapine

Benzodiazepine and Z-Drug Dependence

Pharmacological management focuses on medically supervised withdrawal:

  • Gradual dose tapering of the same benzodiazepine
  • Cross-tapering to longer-acting benzodiazepines (e.g., diazepam, clonazepam)
  • Adjunctive medications for withdrawal symptoms 6

Other Substances

GHB/GBL dependence:

  • Baclofen (GABA-B agonist) 6
  • Benzodiazepines for acute withdrawal

Gabapentinoid dependence:

  • Gradual tapering protocols 6

Critical Implementation Principles

Combination with Behavioral Therapy

Pharmacotherapy should be combined with evidence-based behavioral interventions - the combination is superior to either alone 7:

  • Cognitive behavioral therapy (CBT)
  • Motivational enhancement therapy
  • Contingency management
  • Community reinforcement approach

However, pharmacotherapy should NOT be restricted only to patients whose goal is abstinence - even reductions in use translate to substantial decreases in morbidity (cancer, hypertension, cardiovascular disease, HIV transmission) 1, 2

Harm Reduction Services

All patients reporting drug use should be offered: 2

  • Naloxone for overdose prevention
  • Fentanyl and xylazine test strips
  • Safe use education
  • Referral to syringe services programs

Treatment Access Considerations

For opioid use disorder specifically:

  • As of January 2023, the DEA X-waiver requirement was eliminated for buprenorphine prescribing 3
  • New 8-hour training requirement exists for substance use disorder treatment
  • Buprenorphine can be initiated in office or at home 3
  • Initiation requires patient to be in opioid withdrawal to avoid precipitated withdrawal:
    • Short-acting opioids: ~12 hours since last use
    • Long-acting opioids/methadone: 48-72 hours since last use
    • Fentanyl may require >12 hours 3

Common Pitfalls to Avoid

  1. Do not withhold medications for substance use disorders in patients receiving antiretroviral therapy or hepatitis C treatment - few clinically significant drug interactions exist 2

  2. Do not use brief buprenorphine tapers (medical withdrawal) - associated with high relapse rates; maintenance treatment is indicated 1, 3

  3. Do not delay treatment for co-occurring psychiatric disorders - treat concurrently to maximize outcomes 3

  4. Do not require abstinence before initiating pharmacotherapy - harm reduction is a valid treatment goal 1

  5. For pregnant women with OUD, offer buprenorphine (without naloxone) or methadone - associated with improved maternal outcomes 8

Polysubstance Use Considerations

SUD severity increases with number of substances used - among those with ≥5 substances, 44.4% have severe SUD 9. Comprehensive assessment across all substances is essential, particularly with stimulant or polysubstance use patterns 9.

Related Questions

Can naltrexone be added to a regimen of bupropion, methylphenidate (Ritalin) and agomelatine (Valdoxan) for alcohol cessation?
What are the first‑line pharmacologic treatments for alcohol dependence and how should they be selected based on liver function, cardiac status, and patient preference?
What is the appropriate baclofen dosing regimen for maintaining alcohol abstinence?
A 40-year-old patient on sertraline 40 mg daily and Adderall XR (amphetamine/dextroamphetamine) 10 mg daily reports no improvement; how should the sertraline dose be adjusted and what additional treatments should be considered?
For an adult with alcohol use disorder and liver impairment who wishes to maintain abstinence, should acamprosate or naltrexone be used?
In a patient with sustained ventricular tachycardia and persistent atrial fibrillation requiring high‑dose β‑blocker therapy, what justifies the need for a dual‑chamber implantable cardioverter‑defibrillator?
What are the risks of malignant hyperthermia?
How should low ferritin with normal iron saturation and normal hemoglobin be evaluated and managed?
What is the clinical interpretation of a thyroid panel showing thyroid‑stimulating hormone 2.36 µIU/mL, T3 uptake 36 %, total thyroxine 5.5 µg/dL, free thyroxine 1.9 ng/dL, and thyroglobulin antibodies 5 IU/mL?
What is the recommended dosage of magnesium glycinate for an adult without known kidney disease to improve sleep?
What medication can be prescribed for a herpes simplex virus type 1 (HSV‑1) outbreak on the upper lip or mouth?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.